Mumbai: Aventis Pharma India, a unit of French drugmaker Sanofi-Aventis, expects sales of its diabetes products, the firm’s fastest growing segment, to jump 27 % in 2010 from Rs 180 crore last year, an official said on Wednesday. The company expects sales of insulin to surge 60 % in 2010 from Rs 800 million in 2009, Susheel Umesh, senior director commercial operations, Sanofi-Aventis India, told Reuters.
“There are estimated 50 million people suffering from diabetes in India and only 12.5 million receive treatment,” Umesh said.
“Therefore the growth opportunities in this segment are huge.”
Within the diabetes portfolio, the insulin contributed about Rs 800 million to revenue in 2009, while the rest Rs 100 crore came from oral products.
“Our oral products are made in India, while insulin brands like ‘Lantus´ are imported,” Umesh said.
In 2009, Lantus notched up about Rs 700 million in sales for Aventis Pharma in India, he said.
“While the (insulin) market is growing at 30 % in India, our insulin portfolio is growing at 60 %,” he added.
Last month, Aventis Pharma said its quarterly net profit grew 8 % to Rs 473 million on net sales of Rs 275 crore.
Aventis Pharma’s cardio-diabetes portfolio in India is growing at 21 % annually, faster than other segments like oncology, central nervous system and anti-infectives. Sanofi-Aventis runs its India operations through two firms—Aventis Pharma India and Sanofi-Synthelabo (India).
Aventis Pharma is majority owned by its French parent, while Sanofi-Synthelabo is a fully-owned unit of Sanofi-Aventis.
Shares of Aventis Pharma closed up 0.11 % at Rs 1,887.05, while the larger market ended down 0.3 %.